Cited by 222Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsGenetic Associations and Epidemiology

Genetic Variation and Neuroimaging Measures in Alzheimer Disease

Open access
Biffi, Alessandro·2010·Archives of Neurology

Abstract

OBJECTIVE: To investigate whether genome-wide association study (GWAS)-validated and GWAS-promising candidate loci influence magnetic resonance imaging measures and clinical Alzheimer's disease (AD) status. DESIGN: Multicenter case-control study of genetic and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative. SETTING: Multicenter GWAS. Patients A total of 168 individuals with probable AD, 357 with mild cognitive impairment, and 215 cognitively normal control individuals recruited from more than 50 Alzheimer's Disease Neuroimaging Initiative centers in the United States and Canada. All study participants had APOE and genome-wide genetic data available. MAIN OUTCOME MEASURES: We investigated the influence of GWAS-validated and GWAS-promising novel AD loci on hippocampal volume, amygdala volume, white matter lesion volume, entorhinal cortex thickness, parahippocampal gyrus thickness, and temporal pole cortex thickness. RESULTS: Markers at the APOE locus were associated with all phenotypes except white matter lesion volume (all false discovery rate-corrected P values < .001). Novel and established AD loci identified by prior GWASs showed a significant cumulative score-based effect (false discovery rate P = .04) on all analyzed neuroimaging measures. The GWAS-validated variants at the CR1 and PICALM loci and markers at 2 novel loci (BIN1 and CNTN5) showed association with multiple magnetic resonance imaging characteristics (false discovery rate P < .05). CONCLUSIONS: Loci associated with AD also influence neuroimaging correlates of this disease. Furthermore, neuroimaging analysis identified 2 additional loci of high interest for further study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archneurol.2010.108

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SNPs of BIN1, such as rs744373 and rs7561528, may contribute to AD susceptibility by impacting brain structure and function.

    “In addition, the SNPs of BIN1, such as rs744373 and rs7561528, may contribute to AD susceptibility by impacting brain structure and function [480, 481].”
  • SNPs in and around APOE, BIN1, SORL1, and CR1 have been associated with traits including medial temporal lobe atrophy and cortical thickness.

    “SNPs in and around candidate genes including APOE, BIN1, SORL1, and CR1 have been associated with traits including medial temporal lobe atrophy and cortical thickness [225–228]”

    From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [227]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Biffi, A.
Affiliations
Massachusetts General Hospital (US)
Corresponding author
Biffi, Alessandro
Venue
Archives of Neurology
Published
2010-06-01
Volume
67
Issue
6
Pages
677
ISSN
0003-9942 (ISSN-L)
OpenAlex
W2105172870
Cited by
222
References
36
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 12 · 2021: 9 · 2020: 14 · 2019: 17 · 2018: 14 · 2017: 9 · 2016: 28 · 2015: 14 · 2014: 19 · 2013: 26 · 2012: 14
FWCI
14.83
Type
journal article
Language
en
Open access
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Foundation for the National Institutes of Health (U01AG024904, AG024904)
  • Howard Hughes Medical Institute
  • Ellison Medical Foundation
  • Alzheimer's Association (AG05681, U01 AG024904)
  • American Heart Association
  • Bristol-Myers Squibb (U01 AG024904, AG024904)
  • Eli Lilly and Company (U01 AG024904, AG024904)
  • Pfizer (AG024904, U01 AG024904)
  • GlaxoSmithKline (P01AG03991)
  • Northern California Institute for Research and Education (U01 AG024904)
  • Elan (U01 AG024904)
  • Eisai (U01 AG024904, AG024904)
  • National Institutes of Health (5u01ag024904-10, 6u54rr020278-06, BIRN002, U01-AG024904, AG05681, RR14075, AG024904, NS042861)
  • University of California, Los Angeles
  • University of California, San Diego
  • National Institute on Aging (U01-AG-024904, AG021910, P30AG010129, R01AG021910, R01AG026484, AG 024904, K01AG030514, AG 05681, P 50 AG05681, P50AG005681, P01 AG0 3991, P01AG003991, AG02238, U19AG010483, U24AG021886)
  • National Institute on Drug Abuse (R21DA026104)
  • National Institute of Neurological Disorders and Stroke (R01NS042861, R01NS059727, R01NS052585)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB001550, R01EB006758, U01 AG024904, AG024904)
  • National Center for Research Resources (U54-RR020278, P41-RR-14075, RR 14075, U24RR021382, R01 RR1659401A1, P41RR014075, BIRN002, R01RR016594, U01 AG024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, genetic loci, genome-wide association study, hippocampal volume, amygdala volume, white matter lesions, cortical thickness, apolipoprotein E, complement receptor 1, PICALM, BIN1, CNTN5, mild cognitive impairment, Alzheimer's Disease Neuroimaging Initiative
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Canada, Cognition Disorders, Female, Genotype, Humans, Image Interpretation, Computer-Assisted, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Nuclear Proteins, Risk Factors, United States, Reproducibility of Results, Cell Adhesion Molecules, Neuronal, Logistic Models, Odds Ratio, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review